Enzalutamide
Hormone-Resistant Prostate Carcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsSmall moleculePhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Hormone-Resistant Prostate Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Prednisone University of California, Davis | Phase 3 | BB |
Abiraterone Alliance for Clinical Trials in Oncology | Phase 3 | BB |
Docetaxel Seattle Institute for Biomedical and Clinical Research | Phase 3 | BB |
Bicalutamide Mayo Clinic | Phase 2 | B |
Pembrolizumab University of Wisconsin, Madison | Phase 2 | B |
View all 49 →
Same molecule, other indications
Enzalutamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →